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Mycoplasma gallisepticum, the highly transmissible avian pathogen, is the primary
etiologic agent of chronic respiratory disease (CRD), a disease largely affecting the respiratory
tract of poultry, and causing significant economic losses world-wide. Proteins of the variable
lipoprotein and hemagglutinin (vlhA) gene family are thought to be important for M.
gallisepticum host interaction, pathogenesis and immune evasion, but the exact role and overall
mechanisms of phase-variation are not well understood. To better understand the phase variation
of M. gallisepticum vlhA genes, we have conducted a large scale, next generation sequencing
analysis of M. gallisepticum sampled directly from the tracheal mucosa of experimentally
infected chickens as well as those recovered and passaged in-vitro.
In the first study, M. gallisepticum was recovered from the tracheal mucosa daily over
the course of a seven day infection. Of note, the data indicated that, at given time points, specific
vlhA genes were similarly dominant in multiple independent hosts, suggesting a non-stochastic
temporal progression of dominant vlhA expression. Additionally we found that vlhA expression
was not dependent on the presence of exactly 12 GAA repeats, suggesting a previously
unrecognized mechanism may be responsible, at least in part, for vlhA expression.
In the second study, we report that the vlhA profile of M. gallisepticum recovered from
the trachea of experimentally infected chickens when the input culture expressed an alternate
dominant vlhA, vlhA 2.02. Here we report that even when the culture is dominantly expressing

Katherine M. Pflaum – University of Connecticut, 2016
vlhA 2.02, there is an immediate shift as early as one day post infection to the dominant
expression of vlhA 3.03, suggesting the expression of this gene many be essential in the earliest
stages of the infection process.
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CHAPTER 1: Literature Review

Section 1: General Features

Introduction
Mycoplasmas are very small selfreplicating Prokaryotes that lack a cell well. They
range in genomic size from 580 Kb as seen in M. genetalium (1) to 1,380 Kb as seen in M.
mycoides subs mycoides LC (2) and have very low genomic G+C content (23-40%)(3). They
are believed to have evolved from a low G+C containing Gram-positive bacteria through
degenerative evolution (4, 5).Mycoplasmas also have very limited biosynthetic capabilities,
lacking the ability to synthesize many essential molecules, including purines and
pyrimidines. and hence must rely on close interactions with host cells for essential nutrients
and molecules such as amino acids, nucleotides, and fatty acids. Unique to the mycoplasmas
is the necessity to acquire sterols from host cells to maintain cell membrane integrity without
the support of a rigid cell wall (2). Mycoplasmas uncharacteristically use the traditional stop
codon, UGA to encode the amino acid tryptophan (6, 7). These organisms tend to have a
unusually high mutation rates, likely due to inadequate proof-reading by DNA polymerase
enzymes (5).
Mycoplasmas are common pathogens and tend to exhibit strict host specificity over a
wide variety of species including humans, animals, reptiles, insects and even plants. They
can cause a wide range of diseases, effecting respiratory and reproductive tracts, among other
organ systems. Several mycoplasma species exist however, as commensals, living with their
host species as part of their natural flora. Very few mycoplasma species cause mortality, but
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many are associated with morbidity and have significant economic impacts around the world
resulting from their pathological effects on humans, pets, livestock, and poultry.

History
The first mycoplasma was identified by Nocard and Roux in 1898 (8). A semipermeable nitrocellulose pouch containing sterile peptone broth was inoculated with
infectious exudates from a cow exhibiting signs of bovine pleuropneumonia, including
distention of the interlobular connective tissue by a large amount of clear-yellowish
albuminous serous fluid. This pouch was surgically placed into the peritoneal cavity of a
rabbit, along with an uninoculated control and a heat-inactivated control. Approximately 3
weeks later, the broth containing the infectious exudates became opalescent, while the
controls remained clear. Eventually, Nocard and Roux were able to cultivate this organism
axenically in peptone broth supplemented with serum and experimentally inoculate cattle.
When this organism caused disease in experimentally infected cattle, it was deemed the
etiologic agent of bovine pleuropneumonia and was therefore named, the pleuropneumonia
virus (8). After this initial discovery, much taxonomic contention and confusion would ensue
in the years to follow.
Initially this organism was incorrectly classified as a virus. This was the case because
the organism was able to pass through a filter, which does not allow the typical bacteria to
pass and invisible by light microscopy (9). Additional evidence supporting this theory came
when Eaton et. al. (10) isolated, what he termed Eaton’s agent, which would later come to be
known as Mycoplasma pneumoniae, and it appeared to be unaffected by antibiotics. We now
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know the antibiotics used (β-lactam) work by disrupting the cell wall formation, a process
that mycoplasma species do not undergo, as they lack a cell-wall altogether.
In 1910, Borrel et. al. cultured the organism isolated by Nocard and Roux, that was
thought to be a virus at the time, and saw radiating filamentous structures and therefore
renamed the organism Asterococcus mycoides (11). In retrospect, these structures that were
observed were likely due to contamination (9). Just one year later, Martzinovski et. al.
cultured the same organism and did not see the filamentous structures, but rather diplococcic
and streptococci, and therefore renamed the organism for the third time, Coccobacillus
mycoides (12). Several years later, it was incorrectly characterized as an L-form, or wall-less
form, of other known bacteria, such as the Streptococci due to their similar morphology (13,
14).
By 1935, this group of organisms had undergone seven different name changes. It
was at this time that Klienberger introduced the term ‘pleuropneumonia-like organisms’
(PPLO) to describe these ‘wall-less variants’ of known bacteria (9). It was not until nearly 50
years after the discovery when the Judicial Commission of the International Committee on
Bacteriological Nomenclature in 1958 would rule that the name of the etiologic agent of
bovine pleuropneumonia was Mycoplasma mycoides. It was ten years after that, that the
committee agreed on the class Mollicutes to describe organisms with ‘the absence of a true
cell wall and plasticity of the outer membrane’(9).

Nomenclature
After many years of contention surrounding the taxonomic classification of these
bacteria, the current classification system places the mycoplasmas in the phylum Tenericutes
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which are phyogenically related to the Firmicutes phylum consisting of low G+C content
bacteria such as Bacillus species (2). The only class within the Tenericutes phylum is the
Mollicutes class, which consists of bacteria that lack a cell wall, have an unusually small
genome, and have low G+C genomic content. Mycoplasmas belong to the order
Mycoplasmatales which are known to colonize vertebrates. The Mollicutes in the remaining
four orders including the Entomoplasmatales, Acholeplasmatales, Anaeroplasmatales, and
Haloplasmatales, typically tend to colonize insects and plants. Mycoplasmas are classified
within Mycoplasmataceae, the only family found within the Mycoplasmatales order. The
Mycoplasmataceae family is further separated into two genera, the Mycoplasmas and the
Ureaplasmas which are categorized based to their ability to hydrolyze urea as an energy
source (15).

Minimal Genome Concept
Since M. genitalium harbors the smallest genome for any known self replicating cell
in nature (16), the J. Craig Venter Institute (JCVI) has set out to understand and identify the
minimal complete set of genes that are necessary for growth in a lab setting, using the M.
genetallium genome as their foundation. In 2008 JCVI constructed an organism with a
synthetically created genome based on that of M. genitalium containing what was thought to
be the minimal complement of genes for a free living cell (17). This organism, M. genitalium
JCVI-1.0 contained only 582,970 base pairs.
To further understand the components that are essential to a free living organism,
JCVI constructed a synthetic bacterium based on the genome of M. mycoides (18), the largest
mycoplasma genome containing 1,380 Kb (2). This synthetic organism, JCVI-syn1.0
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contained 1,079 Kb, and contained all the expected phenotypic properties, including
continuous self-replication (18).
Recently, the researchers at JCVI have further defined the minimal complement of
genes required for a free living cell by minimizing the JCVI-syn1.0 through a series of cycles
of design, synthesis, and testing. They were able to reduce the JCVI-syn1.0 from 1,079 Kbs
to 531 Kbs, creating JCVI-syn3.0, an organism with a genome smaller than any known self
replicating organism. JVCI-syn3.0 contains only 473 genes and has an approximate doubling
time of 180 minutes (19).
This work, conducted by JCVI, has begun to define the genes that are essential for a
free living, self-replicating organism using known mycoplasma genomes as their foundation.
Further investigations into these minimal organisms will shed more light on the functions of
previously unknown mycoplasma genes and the essential components of free living, selfreplicating organisms.

Section 2: Infectious Mycoplasma species

Mycoplasmas of Humans
Several Mycoplasma species are able to infect humans including Mycoplasma
pneumoniae, Mycoplasma genitalium, Mycoplasma hominis, and Mycoplasma penetrans.
One of the most studied pathogens in this genus is M. pneumoniae, which causes communityacquired interstitial pneumonia, commonly referred to as walking or atypical pneumonia (20)
and is the predominant cause of pneumonia in school aged children, making this disease a
significant burden to public health (20, 21). Additionally, albeit rare, M. pneumoniae
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infections has been reported to lead to other complications such as encephalitis (22, 23) and
pericarditis (24, 25). There is a close association of M. pneumoniae infection and acute
asthma and Chronic Obstructive Pulmonary Disease (COPD) due to the strong Th2 response
elicited by infection with this pathogen (26–28). Aside from the known pathologies of the
respiratory tract, infection with M. pneumoniae has been linked to renal and gastrointestinal
complications and hemolytic anemia (21). M. pneumoniae is one of only a few species of
Mycoplasma that are known to produce a toxin. The M. pneumoniae gene, MPN_372,
encodes the CARDS (Community-Acquired Respiratory Distress Syndrome) toxin, a ADPribosylating and vacuolating cytotoxin (29) that has been shown to bind human surfactant
protein A and induce allergic-type inflammation in the airway (30).
Cytadherence is a critical initial step in the infection process, as it prevents clearance
by the host. M. pneumoniae display a flask shape appearance with a complex tip structure,
which is described as a slender protrusion from the cell body with an electron dense core(31).
The cytadhesion molecules must be localized to the tip structure to allow for successful
attachment of the organism to host cells. Several proteins are found in the tip structure and
are essential for full functionality of M. pneumoniae attachment including the primary
cytadhesion P1, proteins B and C, P30 and HMW1, 2, and 3 (32).
The tip structure of M. genitalium has been described as very similar to that of M.
pneumoniae with MgPa (homologous to M. pneumoniae P1), the primary cytadhesion
molecule localized to the tip structure (3). M. gallisepticum has a similar tip structure where
the primary cytadhesion, GapA (and homolog to M. pneumoniae P1) and CrmA are essential
for attachment. Pre-incubation of M. gallisepticum with Fab fragments reactive to GapA
inhibited attachment of M. gallisepticum to lung fibroblasts, indicating that it is largely
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responsible for cytadherence (33). In addition, an attenuated strain R (Rhigh) lacking both
GapA and CrmA demonstrates a significant reduction in attachment (34). Interestingly,
complementation of Rhigh with gapA did not restore cytadherence, but complementation of
with both gapA and crmA resulted in the restoration of cytadherence to the level of virulent
strain R, indicating that these two proteins collaborate in the process of cytadherence (34).
It has been reported that when mice are vaccinated with an avirulent M. pneumoniae
P30 cytadhesion mutant, subsequent challenge with a virulent strain surprisingly results in
exacerbated disease than unvaccinated control mice (35). This is not the only report of
vaccine induced disease exacerbation in experimentally infected rodents (36, 37). These
unsuccessful vaccination studies highlight the need to better understand the basic
mechanisms and pathogenesis in order to develop effective therapeutics and vaccines.
Mycoplasma genitalium, another well studied human pathogen, is associated
urogenital complications in both males and females, commonly causing sexually transmitted
non-chlamydial non-gonococcal urethritis in men and pelvic inflammatory disease in women
(38–40). M. genitalium infections occur globally and, while prevalence rates vary by country
and community, human infection has been detected in every country where it has been
sought (41). Unfortunately, the exact mechanism and relationship of M. genitalium and
human disease is still poorly understood. In addition, there is not a single uniform method for
clinical detection of infection, creating a large gap in the understanding of how this pathogen
truly impacts human health. Despite the availability of several qPCR detection kits, none are
FDA approved for clinical/diagnostic use. Additionally, doxycycline, the typical first line
antibiotic for urethritis, is not effective against this pathogen, and resistance to macrolides
has recently been reported (41) emphasizing the need to further understand the pathogenesis
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of this emerging pathogen. Recent technological advances, namely the Nucleic Acid
Amplification Test (NAAT) allowing for rapid and accurate detection, has begun to allow
scientists to perform more studies to start to elucidate the pathogenic mechanism employed
by this emerging sexually transmitted infection (41).
Another infectious Mycoplasma species that is able to colonize the human urogenital
tract is M. penetrans (38). This pathogen was the first identified invasive member of the
Mycoplasma genus and has been reported to penetrate Eukaryotic cell membranes using its
tip structure (42). A correlation was established between M. penetrans and HIV infection
where the rate of M. penetrans infection was significantly higher in patients with HIV,
suggesting they are potential co-pathogens (42). However, subsequent studies have reported
that there is no distinct pathology associated with this infection and no compelling evidence
to suggest that they act do as co-pathogens (43). Host immune evasion is believed to be
achieved in this organism though the phase variation of the Mpl lipoproteins (44, 45),
aggulutination of red blood cells, lymphocytes and monocytes (42) and it has been
demonstrated that M. penetrans can bind IgA, serving as a defense mechanism evading
clearance by IgA specific antibodies (46).
M. hominis, another human pathogen that can inhabit the urogenital tract, is
associated with bacterial vaginosis and have been linked to pre-term births (38). M. hominis
induces the production of inflammatory cytokines and chemokines that are thought to be
responsible for pre-term births and potential brain damage commonly observed in infections
(47–49). A recently identified gene, goiC, appears to be associated with virulence,
specifically related to the bacterial density in the amniotic fluid and pre-term births as
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isolated mutant strains lacking this gene, show a significant decrease in bacterial density in
the amniotic fluid and reduction in pre-term births (50).
Taken together, these data demonstrate the lack of complete understanding of the
pathogenic mechanisms employed by these mycoplasma species that infect humans and
highlight the need for a more complete understanding of these organisms and their virulence
factors.

Mycoplasma of Porcines
Two main Mycoplasma species are known to infect swine and cause significant
economic losses to farmers around the world. M. hyopneumoniae is the causative agent of
porcine enzootic pneumonia, a highly contagious and infectious disease of swine M.
hyopneumoniae can contribute to the super infection known as the porcine respiratory disease
complex (51) . Recent genomic comparisons of a pathogenic strain with a high-passage
attenuated strain identified genes and gene families that are important in the virulence of the
organism, including cytadhesins, cell envelope proteins (P95), cell surface antigens (P36),
chaperone proteins (DnaK), and genes involved in metabolism (52). A significant portion of
the pathogenesis can be attributed to the ability to attach to swine respiratory cells via the
P97 cytadhesion (53) and to bind host glycosaminoglycan heparin sulfate (54, 55).
M. hyorhinis, spread by respiratory secretions, can cause serofibrinous to
fibrinopurlent polyserositis and arthritis in swine (56). Of note P37, a surface exposed
lipoprotein that binds pyrophosphate (57) has been shown to induce tumor transformation of
Eukaryotic cells (58–60). It has recently been reported that the P37 lipoprotein can transform

9

normal gastric cells to cancer cell though activation of the PI3-kinase-AKT signaling
pathway, initially stimulated though the epidermal growth factor receptor (EGFR) (61).

Mycoplasmas of Bovines
The Select Agent, Mycoplasma mycoides subs. mycoides Small Colony (MMMSC)
was the first Mycoplasma described by Nocard and Roux in 1898 (62) and is a highly
contagious respiratory pathogen of cattle that can cause fatal pleuropneumonia (63). This
organism is one of the few species of mycoplasma that causes mortality. MMMSC has been
described as the single most important threat to the cattle industry in Africa and economically
the most important mycoplasmal pathogen in the world (3). The United States has been free
of this pathogen since 1893 (64), however re-emergences of this pathogen has been reported
in Europe as recently as that late 19th century with confirmed cases in Portugal and Italy and
sporadic outbreaks in France and Spain (3). Currently, there are commercially available live
attenuated vaccines, however they provide inadequate protection, require annual boosting,
and can revert to virulence, demonstrating the need for improved vaccines (65). It has been
speculated that MMMSC can evade the host immune system via the phase variable Vmm
lipoproteins, a trait shared with many other mycoplasma species (66). Of interest and related
to the virulence of MMMSC, is the ability to ferment glycerol via the glpO gene (67)
resulting in the production of hydrogen peroxide (68, 69) a reactive oxygen species, that is
known to cause cellular damage to host Eukaryotic cells.
M. bovis, another mycoplasma pathogen of cattle, has been reported to cause mastitis,
(70) pneumonia, (71, 72) and contributes to Bovine Respiratory Disease Complex (73) which
can lead to broncopneumonia. M. bovis has been reported to evade host immune responses
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though the phase and antigenic variation of the surface exposed vsp genes. Of significance is
the membrane associated polysaccharide is an inflammatory toxin that causes mastitis in
cattle when inoculated into the udder (74).

Mycoplasmas of Caprines
M. capricolum subs. capripneumoniae, formally known as the F-38 group of
mycoplasma, is a significant pathogen of goats and the causative agent of Contagious caprine
pleuropneumonia a frequently fatal disease. It has also been reported to cause mastitis and
arthritis (75). This Select Agent is particularly a problem in Africa and Asia, causing
devastating economic losses (3). Little is understood about the pathogenesis and virulence
mechanisms of this organism, but genomic comparisons of the highly virulent and frequently
fatal M. capricolum subs. capripneumoniae and M. capricolum subs capricolum show that
the lppA lipoprotein gene is truncated in M. capricolum subs. capricolum, suggesting it may
be involved in the virulence and pathogenesis (76).
M. agalactiae causes mastitis resulting in the marked decrease of milk production in
small ruminants, causing a significant economic impact (77). The organism is often isolated
from milk samples of infected animals and can be a significant contaminat in milk storage
tanks (78). M. agalactiae can be vertically transmitted from doe to kid through direct contact,
during suckling (77). Virulence determinants of this pathogen includ biofilm formation (79),
hydrogen peroxide production (80), anda

putative cystine desulfurase, nifS

essential for growth inEukaryotic co-culture (81).
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which is

Mycoplasmas of Rodents
M. pulmonis, a respiratory pathogen of mice causes a disease similar to atypical
pneumonia in humans, and can induce allergic airway disease and airway hyper-reactivity
(82), making this organism an excellent model to study the role of both the innate and the
adaptive immune response in the respiratory tract (3). Virulence of this organism is related to
immune evasion via phase variation of the vsa variable lipoproteins (83), which also have
been report to be associated with biofilm formation(84). Additionally, M. pulmonis produces
a hemolysin, nuclease, and a glycoprotease which is of particular interest, as hydrogen
peroxide production has been linked to virulence in other mycoplasma species (85).
M. arthritidis has been linked to polyarthitis in rats and chronic proliferative arthritis
in mice, but has also been reported to have been isolated from animals without arthritis (3,
86). M. arthritidis hydrolyzes arginine to produce energy (86) and contains multiple variable
lipoproteins speculated to be involved in immune evasion (87). Of particular interest, is the
superantigen, M. arthritidis T-cell Mitogen (MAM) (88) which acts by binding the alpha
chain of the MHC II molecule on B cells and the variable Beta chains on T helpers cells,
thereby connecting them (89–91). This linkage results in lymphocyte activation in an antigen
independent fashion leading to the uncontrolled production of inflammatory cytokines and
polyclonal antibodies (92, 93).

Mycoplasmas of Felines
M. felis was originally isolated from a cat with severe conjunctivitis (94) and has seen
been linked with pneumonia (95). Interestingly, it has also been reported to cause pleuritis
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(96) and lower respiratory tract diseases in horses (97). M. gateae has been reported to cause
erosive polyarthritis and synovitis in felines (98, 99).

Mycoplasma of Canines
There have been 15 species of mycoplasma isolated from or detected in dogs, (100)
however their roles in respiratory infections is not well understood. They are thought to be
part of the normal flora of the upper respiratory tract but have been observed colonizing the
lower respiratory tract during infections such as pneumonia (101). M. edwardii and M.
spumans have been associated with respiratory diseases in dogs. M. cynos has been reported
to cause respiratory disease in young dogs and has been associated with canine infectious
respiratory disease (CIRD) (100) and M. canis causes urinary tract infections and can lead to
infertility (102). These two pathogens in addition to M. molare, secrete sialidase, a feature
unique to these species in the genera, as other mycoplasma species have membrane bound
sialidase (103). Sialidase has been associated with virulence in other species, such as M.
gallisepticum, where a transposon insertion mutation in the sialidase gene demonstrated
reduced lesions and recovery in experimentally infected animals (104). Sialidase has also
been associated with virulence in M. synoviae where it was reported that those strains
demonstrating higher virulence exhibited significantly higher levels of sialidase activity
suggesting an enzymatic basis for virulence (105). However, to date, the role of secreted
sialidase in the virulence of these canine pathogens still remains unknown.
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Mycoplasmas of Reptiles and Piscines
In 1995, an epidemic of acute multisystemic inflammatory disease was discovered in
captive alligators in Florida. Four years later it was confirmed that the etiologic agent was the
flesh-eating bacterium, M. alligatoris (106). Infection results in interstitial or fibronecrotic
pneumonia with fibrinous polyserositis and multifocal arthritis (107). Identified potential
virulence factors in this organism include hyaluronidase and sialidase which have been
shown to induce the CD-95 signaling pathway, resulting in apoptosis of Eukaryotic cells
(108).
The closely related M. crocodyli (98% 16s rRNA similarity) shows a comparaitivly
reduced virulence in crocodiles, which could be due, at least in part, to the lack of sialidase
(109). It has been reported that while M. alligatoris contains both hyaluronidase and
sialidase, genome comparisons suggest that M. crocodyli contains only hyaluronidase and
lacks sialidase (109). This further emphasizes the link between the enzymatic activity of
sialidase in mycoplasmas and virulence. Another mycoplasma pathogen of reptiles, M.
agassizii, emerged during the late 1900’s causing rhinitis with palpebral edema and serous
nasal and ocular discharge in the desert tortoise (110, 111).
The only known mycoplasma species to infect fish, M. mobile, can cause severe
necrosis of the gills of infected fish (112, 113). Interestingly, this species is the fastest motile
mycoplasma and is considered to be the model organism for gliding motility in which M.
mobile, and other motile mycoplasma species, are able to glide on solid surfaces without
containing any flagella, pili, or gene homologs to any known motility systems. M. mobile is
able to move by gliding motility and is explained though a model termed the ‘centipede
model’ (114). During motility, the tip structure protein Gil349 attaches to sialic acid residues
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on host cells and ATP is hydrolyzed, providing the necessary energy. This causes a
conformational change, which physically moves the mycoplasma forward. The next sialic
acid is released and the process is repeated (114).

Mycoplasmas of Avians
M. synoviae has been implicated in infectious synovitis, respiratory lesions, and
airsacculitis in poultry (115). Virulence determinants likely include immune evasion via the
phase variable vlhA lipoproteins (116) and sialidase activity (104). However, reliable
methods for specific gene mutations have not yet been developed for M. synoviae, making it
difficult to directly assess how a specific gene is related to the virulence of the organism.
Despite these potential virulence factors, the disease is well controlled in poultry with the use
of a live attenuated vaccine (117–119).
M. iowae has been reported to cause airsacculitis, embryo mortality, and physical
abnormalities in infected poultry (115). It is resistant to bile salts (120) and commonly
isolated from the digestive tract of infected embryos (121). Interestingly, M. iowae is able to
both ferment glucose and hydrolyze arginine, two processes that are usually not seen together
in an individual mycoplasma species (122).
Several other avian mycoplasma species have been identified including M.
gallinarium, which has been reported to cause mild respiratory signs in geese when
concurrently infected with parvovirus, M. columbinasale which causes rhinitis and
pharyngitis in pigeons, and M. anseris which has been reported to cause lesions in geese in
conjunction with M. cloacale. Additionally M. meleagridis has been reported to cause
sinusitis, airsacculitis, and infection of the genital tract of turkeys (123).
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Spiroplasmas and Phytoplasmas
Spiroplasmas and Phytoplasmas, belonging to the class Mollicutes, are mostly plant
pathogens that have a dual host life cycle dependent on sap-feeding insects for transmission
between plant hosts. The sap-feeding insect vectors, including planthoppers, leafhoppers, and
psyllids, acquire the bacterium by ingesting the phloem of infected plants (124). Upon
ingestion, the bacteria reach the mid-gut lumen and must traverse the gut epithelial cell layer,
by aligning the tip structure between the microvilli, to reach the circulatory system. To be
transmitted to the new plant host, the organism must reach the salivary glands and become
incorporated into the salivary secretions of the insect host (124). Little is understood about
the molecular mechanisms of pathogenesis in these plants pathogens as they are un-cultivable
in axenic media, but it has been demonstrated that this dual host lifestyle requires the
organism to successfully pass many physical barriers and requires several specific proteinprotein interactions between the bacterium and insect host.
These pathogens can infect a wide range of plants (3, 124–126) causing a significant
economic impact around the world and have been linked to horseradish brittle root disease,
citrus stubborn disease, and grass stunt disease among others (125, 127, 128). The Aster
Yellows phytoplasma strain Witches’ Broom infection leads to phyllody (conversion of
flowers to leaf-life structures), virescence (greening of floral organs), and Witches’ Broom
(increased proliferation of stems). These changes are particularly beneficial for the bacteria,
as they make the plants more attractive to the insect vectors, enhancing the spread of the
bacteria (124, 126, 128). While little is understood about the pathogenic mechanisms of these
organisms, it has been reported that the Aster Yellows phytoplasma strain Witches’ Broom is
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able to release effector proteins inside the phloem of the plant, including the recently
identified Sap54, which has been linked to the observed pathologies. This novel virulence
factor functions by inhibiting floral development by promoting the degradation of the plant
MADS transcriptions factors which have an essential role in flower development (124).

Section 3: Mycoplasma gallisepticum

Disease and Significance
Mycoplasma gallisepticum is largely a respiratory and reproductive pathogen of
poultry. Infection with virulent strains, such a strain Rlow, lead to clinical manifestations
including tracheal lesions, airsacculitis, inflammation, metaplasia, loss of cilia, and
thickening of the tracheal mucosa (129). Early lesions are typically composed of heterophils
and macrophages, while later lesions contain large numbers of lymphocytes with high
proportions of T-cells (130). The clinical impacts of this include coughing, sneezing,
respiratory rales, and nasal and ocular discharge (131) . If this pathogen is not cleared by the
host, it can cause a chronic disease state (2).
M. gallisepticum contributes to Chronic Respiratory Disease (CRD), a polymicrobial
syndrome largely effecting the respiratory tract, yet also affecting other organ systems, such
the reproductive tract (132, 133). Concurrent infectious with Avian Influenza virus (AIV)
(134), Newcastle disease virus, infectious bronchitis virus (135), pathogenic E. coli,
Haemophilius , and avian rhinotracheitis virus (136) have been reported to enhance clinical
signs associated with CRD. The exact sequence and pathogenesis of co-infecting organisms
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and CRD is poorly understood at this time. However, Sid et al., recently reported that coinfection with M. gallisepticum and AIV promoted bacterial growth, inhibited antiviral gene
expression and affected AIV attachment to the host cell by desialylation of α-2,3 linked sialic
acids (134), beginning to elucidate the biological mechanisms involved in co-infection.
M. gallisepticum is transmitted throughout the flock via horizontal transmission from
inhalation of respiratory droplets from infected birds or through conjunctival exposure (136,
137). Additionally, M. gallisepticum can spread via vertical transmission from the layer to
the egg (138).
Infection does not usually result in mortality, especially in older chickens, but the
morbidity has significant adverse effects to poultry industries around the world due to the
necessity to cull positive flocks and condemn and downgrade carcasses, decreased egg
production and hatchability, decreased egg quality, and a substantial reduction in weight gain
(139, 140). The economic losses to the poultry industry are substantial as it is estimated to be
$588 million per year lost in broiler industries alone in the United States with an additional
$132 million lost from the egg laying industry (115, 141, 142).
Because of this and other significant poultry diseases, the United States Federal
Government implemented the National Poultry Improvement Plan (NPIP) in the 1960’s, a
collaboration between both state and federal departments of agriculture to use new
technology to improve poultry and poultry products throughout the United States by
establishing guidelines for control of M. gallisepticum (and other significant poultry
pathogens such as M. synoviae, Salmonella, and avian influenza) in primary breeder flocks
(143). Because of the severe economic impact, rapid spread, and chronicity of this infection,
M. gallisepticum was determined to be one of the top 3 most significant avian pathogens to
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U. S. poultry producers at the USDA ARS/CSREES National Animal Health Program
Planning Workshop (144).
The current strategies employed by commercial farms include strict biosecurity
measures, antibiotic therapy, and vaccination programs to attempt to prevent and/or control
disease. However, medications cannot effectively be used to eliminate infection from an
entire flock and therefore is not an adequate long-term solution. In severe cases, culling of M.
gallisepticum positive flock is also used to control infection and spread of this important
disease (145).
M. gallisepticum has been shown to cause significant pathology in other species
causing infectious sinusitis in turkeys and conjunctivitis in house finches (2, 146) which
could promote the spreading, especially between back-yard flocks. Biosecurity measures
have been put in place on many farms to prevent such spread (147). Of particular interest is
the emergence of a new strain of M. gallisepticum that was identified in house finch
(Carpodacus mexicanus) populations in the eastern United States in 1994 (146). M.
gallisepticum has also been isolated from many other species of passerine birds such as
purple finches, blue jays, and American goldfinches (148–150). This M. gallisepticum strain
was shown to be genotypically different from the poultry strains by Random Amplification
of Polymorphic DNA (RAPD) and Amplified-fragment length polymorphism (AFLP)
analysis (151) and caused severe conjunctivitis in the house finches (149). Interestingly, only
minimal to mild disease was displayed when these house finch M. gallisepticum strains were
used to experimentally infect poultry (152).
However, over the course of the epizootic event, the house finch-related M.
gallisepticum strains demonstrated increased virulence in the house finch host, but a
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significant reduction in virulence in experimentally challenged poultry, indicating possible
reciprocal evolution of house-finch related M. gallisepticum virulence in house finch and
poultry hosts (S. Geary, unpublished data). Of note, is a recent study comparing the genomic
changes in the M. gallisepticum house finch strains between the initial index case in 1994 and
seven other isolates separated both spatially and temporally (153). The data indicated that the
most dramatic genomic differences were observed in the phase-variable lipoprotein
hemagglutinin genes vlhA in both presence and genomic location, suggesting a potentially
important role of these genes in the virulence of this pathogen (153)

Current M. gallisepticum Vaccines
Over the years, several attempts have been tried to develop an efficacious and safe
vaccine to protect poultry from M. gallisepticum infection. To date, two types of
commercially available vaccines exist, bacterins and live attenuated vaccines. Bacterins,
which are inactivated suspensions of whole organisms, initially seemed promising in the field
as vaccinated and challenged birds showed a lack of clinical signs and reduced air sac lesions
upon gross examinations (154). Furthermore, it was demonstrated that the use of bacterins as
vaccines reduced the decline in egg production associated with M. gallisepticum infection
(154–157) and prevented vertical transmission (158). Unfortunately, later reports showed that
the reduction in bacterial load was only minimal, at best (159) and microscopic lesions, while
less severe, were still present (160). Furthermore, the use of bacterins did not protect against
infection with heterologous M. gallisepticum strains (154–157, 161).
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Meanwhile the live attenuated vaccines were being evaluated and compared to the
bacterins, showing potentially more promising results. The live F strain vaccine derived from
a naturally attenuated strain, was first identified in 1956 (162). Since it was first identified,
several safety and efficacy studies have been conducted in both chickens and other poultry.
In chickens, the live F strain vaccine elicits a strong serological response and, in fact, that
response is the strongest of any commercially available M. gallisepticum vaccine (163). That
serum antibody response, however, is not comparable in magnitude to that of a chicken
challenged with pathogenic M. gallisepticum strain Rlow (164). Vaccination with live F
strain provides good protection for layers while inducing no lesions (141, 165, 166). This
vaccine strain is able to displace the virulent R strain from infected flocks (167) which has
been suggested to a possible mechanism of protection as the F strain out-competes the
virulent strains in the airway, reducing the bacterial load (168). Of note, the F strain vaccine
has been demonstrated to be readily differentiated from field strains through the use of
Western blotting and RAPD fingerprinting (169, 170). Most importantly, vaccination with
the live F strain prevented the development of lesions and disease in birds when vaccinated
birds were subsequently experimentally challenged with virulent strain Rlow (139, 171, 172).
However, the live F strain vaccine was not optimal in all conditions. Vaccination caused
severe lesions and disease in turkeys and young chickens (173) and demonstrated the ability
to pass vertically to the egg (174). In addition, vaccination with the live F strain has been
linked to adverse effects in the reproductive performance in layers, causing a reduction in
total egg production due to a delay in lay onset (165, 175, 175). Furthermore, transmission to
naïve poultry has been reported (176) which is of concern to farmers, as chickens and turkeys
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are often kept in close proximity, creating the possibility of transmission from a vaccinated
chicken (177).
Despite the negative impact the F strain vaccine has on the layers, it has been reported
that F strain vaccinated birds that have been subsequently challenged with a virulent Rlow
strain, have a higher and more successful laying rate and display less vertical transmission
than their unvaccinated counterparts (141, 161). Despite the obvious safety concerns
surrounding the live F strain vaccine, it still elicits a strong antibody response and provides
complete protection against challenge, fairing far better than any other commercially
available vaccine (163).
Another live attenuated vaccine, the ts-11, a temperature sensitive mutant has been
generated though chemical mutagenesis (178). This strain, which is administered via eye
drop displayed a temperature sensitive phenotype with a maximum growth temperature of
33°C, well below the body temperature range of the chicken (40.6° to 41.7°C) and is unable
to permanently colonize the lower respiratory tract. The ts-11 strain is, however, able to
colonize the upper respiratory tract of the chickens, where the temperature is lower, and
stimulate a protective immune response. ts-11 has been demonstrated to be safe in both
chickens and turkeys as it did not cause clinical signs or disease. Minimal lesions were
observed in less than 10% of animals and egg production remained normal (179–181).
However, while a safer option, ts-11 does not always provide protection from challenge and
the level of protection is variable (180, 181). When assessed, it was determined that the
magnitude of the antibody response was very low, which was likely the key reason for the
inconsistent protection reported (180, 182, 183). The ts-11 strain has been shown to persist in
vaccinated animals for several months (179) with limited horizontal transmission (183) and
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no reported vertical transmission to eggs (184). The egg quality is not adversely effected by
vaccination (185) and in fact layers demonstrate an increase in egg production when
vaccinated and subsequently challenged, compared to their unvaccinated counterparts (184).
While the ts-11 strain is unable to displace the virulent Rlow strain in infected birds, it has
been reported to be able to displace the F strain (186). Even though the live attenuated,
temperature sensitive ts-11 vaccine strain may not be able to provide as much protection as
the live F strain vaccine, it is the safer option, especially for turkeys and young chicks.
The final commercially available, live attenuated vaccine is the 6/85 vaccine which
was generated though serial passage in-vitro (163, 179). This vaccine strain was found to be
safe in both chickens and turkeys demonstrating the formation of only few mild lesions in a
small percentage of experimental animals (187) with no effect on egg production or egg
quality (188). However, the efficacy of the vaccine in birds challenged with a virulent strain
is variable and weak (187) and elicits minimal to no detectable serum antibody response
(163). The vaccine strain is unable to prevent the spread of the challenge strain from
vaccinated animals or displace virulent strains from infected birds (186, 189). More
concerning is the report of 6/85-like strains being recovered from un-vaccinated animals,
suggesting the possibility of reversion of this vaccine to virulence (190). However, this
reversion has not yet been successfully reproduced experimentally (191) and the isolated
strain was unable to produce disease in experimentally infected animals (190).
The availability of efficacious and safe vaccines that can be administered to an entire
flock of animals is significantly lacking at this point in time. On one side there is the live F
strain vaccine, which elicits high antibody titers and provides sufficient protection, but is
virulent in young chickens and turkeys. On the other side, there is the ts-11 and 6/85 vaccine
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strains which are much safer and cause mild to no adverse effects, but do not provide
sufficient protection to the flock against virulent M. gallisepticum strains. This demonstrates
the need for the development of a single efficacious and safe vaccine to protect poultry from
M. gallisepticum infections.
The Center of Excellence for Vaccine Research (CEVR) at Uconn has produced two
live attenuated vaccine strains to protect chickens from infection. One of the vaccines was
created by complementing an avirulent strain with a cytadhesin molecule, while the other
strain was developed by disrupting a known virulence factor in a virulent strain. The first live
attenuated vaccine was created by complementing the avirulent Rhigh strain with the
cytadhesin gene gapA. This resulting strain was termed GT5. It was demonstrated that GT5
was safe at high doses and prevented lesions when vaccinated birds were challenged with
virulent strain, Rlow. The same study reported increased production of M. gallisepticum
specific IgG but surprisingly not IgA (192). It was reported that lymphocytes were arranged
in organized follicles and both M. gallisepticum specific IgA and IgG mucosal plasma cells
were produced as early as four days post-vaccination (193).
Mg7 was the second live attenuated vaccine developed by CEVR. It was created by
disrupting the metabolic gene lpd via transposon mutatgenesis in the virulent strain, Rlow.
This vaccine displayed complete attenuation in experimentally infected animals (194). Much
like GT5, this vaccine strain was safe at high doses and prevented colonization and therefore
lesion formation when challenged with the virulent Rlow strain. Similarly these vaccinated
birds produced increased amount of M. gallisepticum specific IgG (168).
Unfortunately these live attenuated vaccine strains were created using transposon
insertions, containing a gentamicin selectable marker, making them unsuitable for
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commercial production in their current forms. Despite that, both vaccines have passed the
“proof-of-concept” stage of development and are superior in performance to ts-11, 6/85 and
the F in laboratory-controlled studies (168). Geary et. al. believe that the need to develop a
rationally designed, safe, and efficacious vaccine still exists and that further knowledge of
the pathogenic mechanisms employed by this organism are necessary to accomplish that
goal.

M. gallisepticum Virulence Factors
Adequate understanding regarding the mechanisms of pathogenesis of M.
gallisepticum are lacking, but significant strides have been made in elucidating the genes and
pathways related to virulence, especially after the complete genome was sequenced (195) and
compared to Rhigh, an avirulent high passage mutant (196). There were several genes
identified as absent in Rhigh, including the major cytadhesin gapA and the gene encoding the
cytadhesin associated molecule CrmA (196). An essential first step in colonization of any
pathogen is cyadhesion as it prevents mechanical clearance by the host. Despite some
differences, GapA and CrmA are homologs of the well characterized P1 and B/C adhesion
molecules of M. pneumonia (33, 34, 197) . As previously discussed, complementation of
Rhigh with gapA or crmA alone did not restore cytadherence or virulence of the organism to
wild-type levels. However, complementing with both gapA and crmA did in fact restore both
cytadherence and virulence of the organism (34). Additionally, it has been demonstrated that
transposon insertion mutations in the virulent Rlow gapA and crmA genes abolish the
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cytaherence capabilities and significantly diminish the virulence of the organism in the
natural host (198) further linking these two genes to virulence of M. gallisepticum.
Two additional genes that were found to be lacking from the avirulent Rhigh strain
were the genes responsible for fibronectin binding, hlp3 and plpA(196). These products were
identified when the peptides that exhibited similarity to known fibronectin binding proteins
were shown to bind the gelatin/heparin-binding domain of fibronectin (199). PlpA
demonstrated homology to the well-characterized cytadhesin associated protein P65 of M.
penumoniae (pneumoniae-like protein A) and Hlp3 demonstrated homology to the
cytoskeletal protein of M. pneumoniae, HMW3 (HMW3-like protein) (199).
Virulence has been linked to proteins involved in metabolism in many pathogens (67,
68). The metabolic protein, dihydrolipoamide dehydrogenase (lpd) is a part of the pyruvate
dehydrogenase complex pathway, a pathway responsible for the production of ATP during
glycolysis. When a transposon mutant was generated via an insertion in the lpd gene of M.
gallisepticum, the organism was completely attenuated and was no longer able to be
recovered from experimentally infected birds (194). This attenuation was likely the result of
the inability of the organism to produce sufficient amounts of ATP and therefore energy for
survival in the host (194).
Another metabolism-related gene, malF has been reported to be essential for the
persistence of M. gallisepticum in experimentally infected birds. When a transposon mutation
was made in this predicted ABC sugar transport permease gene, the organism was unable to
be recovered from experimentally infected bird or cause disease, suggesting its necessity for
persistence (200).
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MslA is an immunogenic mycoplasma-specific lipoprotein that exhibits reduced
expression in the live attenuated F strain vaccine (201). When a transposon mutant disrupting
mslA was created, the organism showed reduced recovery and attenuated virulence in
experimentally infected chickens (201). Since homologs of this lipoprotein are only found in
mycoplasma species, it was coined mycoplasma-specific lipoprotein A (mslA). While its
relationship to the virulence of M. gallisepticum has been demonstrated, the exact role it
plays is not yet completely understood. However, it has been hypothesized that MslA binds
Toll-like receptors (TLRs) which in turn activate NF-κB, leading to the production of
cytokines and chemokines that result in inflammation (201).
The M. gallisepticum gene, MGA_0329, a homolog of sialidase in M. pneumoniae
has been linked to virulence in M. gallisepticum. A transposon mutant disrupting the gene,
resulted in loss of sialidase activity and when used to experimentally infect chickens, showed
significantly less severe tracheal lesions and mucosal thickening in addition to a significant
reduction in bacterial recovery (104). However, complementation restored wild-type levels of
sialidase activity, but did not restore the virulence. This was surprising as sialidase
production has been shown to correlate with virulence in the closely related, M. synoviae
(105) as strains with increasing levels of sialidase activity showed increased virulence in-vivo
while those strains with less sialidase activity produced mild to no respiratory lesions in
chickens (105). It has been hypothesized that since sialylation protects against the hydrolysis
of glycosidic bonds on the host cell surface and degradation of the host cell extra-cellular
matrix, removal of these sialic acid residues can expose new host antigens and play a role in
autoimmune complications of infections (202). These data suggest that the link between
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sialidase activity and virulence is more complicated than originally thought in M.
gallisepticum, and not completely understood at this time.
Several mycoplasma species (M. bovis for example) have the ability to ferment
glycerol and produce hydrogen peroxide, a potent reactive oxygen species known to cause
cytotoxicity in Eukaryotic cells (67, 68). Surprisingly, when transposon mutants were created
in the M. gallisepticum glpO, glpK, and glpF genes of the glycerol transport and utilization
pathway, the organism still retained virulence as evidenced by typical lesions in the tracheas
of infected chickens, suggesting glycerol metabolism and hydrogen peroxide production is
likely not a virulence factor in M. gallisepticum, as previously hypothesized. These data
demonstrate that the function of this pathway is not yet understood in M. gallisepticum.
Potentially tied to the virulence of M. gallisepticum is the phase-variable lipoprotein
hemagglutinin gene family (vlhA) (153). This gene family, further discussed in detail below,
has been reported to display significant genomic changes in size and location between strains
with varying levels of virulence suggesting they may play a role in the virulence of M.
gallispeticum (153).

Section 4: Phase and Antigenic Variation in Mycoplasma

Mycoplasma species have demonstrated the ability to establish chronic infection in a
wide range of host species, even when faced with strong immune pressure. This success may
be due, at least in part, to the ability of these organisms to rapidly change the expression and
size and even the structure of their surface exposed proteins. These events lead to a dynamic
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and plastic cell membrane allowing for rapid adaptations to the environment, enabling the
bacteria to escape host immune pressures and enhance host interactions providing the
bacteria with optimal chances for survival (203).
Phenotypic variation encompasses both phase (the on/off expression of a given
antigen) and antigenic variations (the expression of alternate forms of a given antigen)(203).
At least four molecular strategies have been described in mycoplasma species that affect the
expressed antigens. They include (1) on/off switching via DNA slippage and point mutations,
(2) surface antigenic variation via DNA rearrangement (site-specific DNA inversions), (3)
domain shuffling via homologous recombination, and (4) epitope masking and unmasking
(203).

DNA slippage
Among mycoplasmas, the first antigenic variation mechanism described was the vlp
genes of the procine pathogen, M. hyorhinis. These genes are control by a molecular switch
involving DNA slippage (slipstrand mutations) in the promoter region (204–206). The vlp
gene family contains 3-8 genes designated A-G, each representing a single transcription unit
with a poly-A tract in the promoter region (207, 208). Elongation or contraction of this polyA
tract by a single nucleotide is sufficient to abolish transcription (206). The change in length
causes structural alternations in the DNA curvature, no longer presenting an optimal
conformation for transcription initiation (206). These genes also demonstrate size variation
through intragenic expansion and contraction of tandem repeat regions, wherein it has been
reported that variant cells expressing a long vlp appear to be resistant to antibody mediated
growth inhibition, while the short versions are susceptible (209).
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A similar mechanism has been reported for the phase-variable cytadhesin gene, maa2
in M. arthritidis where the gene is only expressed when it is preceded by exactly 16 thymine
residues (210). Similarly, phase variation of the vmm gene of M. mycoides subs. mycodies SC
and the vmc of M. capricolum subs. capricolum are under the control of reversible promoter
mutations (66, 211). These genes are expressed when the poly-TA tract contains exactly 10
di-nucleotide TA repeats (66, 211). Additionally, the expression of the vaa gene of M.
hominisis depends on the insertion/deletion of adenine residues in the poly-A tract, where
mutations result in the production of an in-frame stop codon and truncated protein (212).
M. gallisepticum contains the phase-variable lipoprotein hemagglutinin gene family
(vlhA, previously referred to as pMGA) which consists of 43 closely related genes distributed
across 5 loci, totaling just over 10% of the gene in strain Rlow (195). Previous studies
initially indicated that only one vlhA gene was expressed at any one time, however
subsequent studies have shown that more than one gene can be expressed simultaneously in a
population. (213, 214). vlhA expression has been reported to be dependent on the presence of
exactly 12 GAA tri-nucleotide repeats upstream of the expressed gene and is believed to
change via slip-stranded mutations in the promoter regions (117, 214–216). It has also been
hypothesized that vlhA gene expression is stochastic, driven by anti-VlhA mediated negative
selection and resulting in random outgrowth populations (117). The exact function of the
VlhAs are still unknown, but has been speculated to involve immune evasion during the
infection process (217) and variation has been loosely associated with virulence in other M.
gallisepticum strains (153). Additionally it has been suggested that the ability of the gene
products to bind red blood cells could be a factor to aid the dissemination of the organism
thought the infected host (218). Reports have also suggested that VlhAs may function in a
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weak initial attachment of M. gallisepticum to target host cells. Despite these data, with
recent technology a current study, described in detail in chapter 2, suggests that another
mechanism is, at least in part, responsible for the control of vlhA gene expression (219).

DNA rearrangement
Many mycoplasma species can achieve phase variation by DNA inversion via site
specific recombination, which is processed by a specific recombination enzyme. This ‘cutand-paste’ process uses two specific and inverted DNA sequences to alternate silent genes
behind a functional promoter (203). There are three well described systems where a single
gene is placed behind a functional promoter while all other genes are silent and they include
the vsa gene family of M. pulmonis (220, 221), the vsp genes family of M. bovis (222, 223)
and the vpma gene family of M. agalactiae (224, 225). All of these bacteria have a sitespecific recombinase that recognizes a specific short DNA sequence as a target for
rearrangement lying adjacent to the phase-variable locus (226).

Homologous recombination
The third type of genetic mechanisms that has been described is homologous
recombination which can be non-reciprocal, reciprocal, or intra-chromosomal (203). Nonreciprocal recombination or gene conversion has been demonstrated in the phase-variable
vlhA gene family of M. synoviae and the MgPa enconding gene of M. genitalium while
reciprocal recombination has been reported in the MgPar elements of M. genitalium (227–
231). The vlhA family of M. synoviae consists of a single transcriptionally active unit and
multiple homologous pseudogenes, lacking a coding sequence, located 5’ to the vlhA gene.
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Antigenic variation occurs from unidirectional recombination between the donor psuedogene
and the functional vlhA, resulting in the duplication of the pseudogene and total loss of the
previously expressed gene. (227, 232). Intrachromosomal recombination has been reported
for the vsp locus of M. bovis, which results in the generation of a chimeric variable
lipoprotein (223). Each potential vsp is preceded by a homologous sequence that serves as
the region for site specific DNA inversion (223).

Epitope masking and unmasking
The fourth mechanism of phenotypic variation, epitope masking and un-masking
demonstrates how a constitutively expressed gene could contribute to the plasticity of the cell
surface (203). This process involved one constitutively expressed antigen and a phase
variable counterpart which may not actually be the target of the host immune repose. During
this process, the phase variable, surface exposed component can physically mask another
surface antigen. This has been descried for the P56 and P120 proteins of M. hominis where
the phase variable P120 is able to mask the constitutively expressed P56 (203).
This process has also been described in detail for the previously discussed phase
variable vlp genes of M. hyorhinis. The products of three genes, vlpA, B, and C are subjected
to size variation though the intragenic expansion and/or contraction of tandem repeat regions,
resulting in long and short variation of M. hyorhinis. Those expressing the long variants are
completely resistant to immune serum antibodies where the short version variants are not.
The target of the serum antibodies are not the vlp genes, but rather another neighboring
surface exposed molecule that is masked by the expression of the long vlp variant and
exposed when the short vlp variant is expressed (209).
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These changes, regardless of the specific mechanisms, allow for the rapid adaptations
to the changing environment, helping the organisms evade host immune responses and
express the most advantageous suite of genes to best persist in the current environment.

Section 5: Mycoplasma Transcriptomics

In order to further elucidate the pathogenic mechanisms employed by these infectious
mycoplasma species, there has been significant effort in the field to understand the
transcriptomics of the organism, both in-vitro and in-vivo. The lack of obvious homologs of
traditional bacterial transcriptional regulators and signaling factors had initially led to the
thought that mycoplasmas were unable to regulate transcription by conventional
mechanisms. This absence, combined with the single identified sigma factor, has led to the
supposition that differences in gene expression in mycoplasma species are due to population
selection and heterogeneity rather than more traditional mechanisms.
Using microarray analysis, it has been demonstrated that the human pathogen, M.
pneumoniae up-regulates the expression of 47 genes, including the conserved heat shock
genes dnaK, ionA, and clpB when the organism was incubated in heat shock conditions
(43°C) for 15 mintues (233).It has also been reported that the porcine pathogen, M.
hyopneumoniae differentially expresses 27 different genes when the organism is exposed to
low iron growth conditions (234) and undergoes significant transcriptional changes in
response to growth in heat shock conditions and in the presence of oxidative stress (235,
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236). Of particular importance, was a study conducted by Cecchini et al (237) where RNA
was extracted from M. gallisepticum cells co-cultured with MRC-5 human lung fibroblast
cells for one hour. In comparison to control cells, M. gallisepticum displayed 58 genes that
were differentially expressed when interacting with the human lung cells. The incubation
time of this study was only one hour, a timeframe less than that of the generation time of a
mycoplasma cell, suggesting that the observed changes in gene expression where, in fact, a
result of exposure to lung cells and not a result of the outgrowth of a subpopulation.
In a comprehensive RNA sequencing analysis, using a combination of spotted arrays,
strand-specific tilling arrays, and transcript sequencing, looking at differential gene
expression in M. pneumoniae, Guell et al reported differential gene expression in a wide
variety of conditions including increased temperature, varying pH, minimal media, and
antibody pressure (238). Of interest, it was reported that there were frequent antisense and
alternate transcripts and multiple regulators per gene indicating a very dynamic and complex
transcriptome that is similar to conventional bacteria such as Escherichia coli and Bacillus
subtilis. (238).
Additional transcriptomic studies in mycoplasma species have found heat shock
proteins up-regulated in M. gallisepticum upon exposure to increased temperatures (239), upregulation of genes important in the virulence (cysP, nanH, vlhA, and a nuclease) of M.
synoviae upon co-incubation with chicken chondrocytes (240), and differential expression of
lipoproteins and nutrient acquisition genes in M. hominis upon exposure to human dendritic
cells (241).
A recent study was conducted by Ron et. al., to identify candidate targets proteins
associated with infection by using in-vivo induced antigen technology (IVIAT). This study
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showed that there were 13 proteins preferentially expressed during in-vivo infection
including previously identified virulence factors, GapA, PlpA, Hlp3, VlhA 1.07, and VlhA
4.01. In addition it was also found that several transport and translation related proteins and
the chaperone protein GroEL were also preferentially expressed in an in-vivo infection (242).
Collectively these data demonstrate that mycoplasma species do, in fact, have the
ability to alter their transcription in response to external stimuli and may undergo significant
changes, including the up-regulation of virulence related genes, in response to changes in the
environment and exposure to potential host cells.
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Hypothesis and Specific Aims

Hypothesis
The phase-variable vlhA gene expression profile of M. gallisepticum will change over
the course of early infection in the natural host in a coordinated, non-random manner.

Specific Aims

Specific aim 1: Investigate and characterize the vlhA gene expression profile of M.
gallisepticum before and during the course of early infection in the natural host.

Specific aim 2: Determine the changes in the vlhA gene expression profile in M.
gallisepticum recovered directly from the trachea mucosa of infected chickens and serially
passed in-vitro in a nutritive medium. The second goal of this aim will be to determine the
necessity of exactly 12 GAA trinucleotide repeats for the expression of any given vlhA.

Specific aim 3: Determine and characterize the M. gallisepticum vlhA trnscriptional profile
over of the course of early infection when expressing a different initial predominant vlhA at
time of challenge.
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Abstract
Mycoplasma gallisepticum is the primary etiologic agent of Chronic Respiratory
Disease in poultry, a disease largely affecting the respiratory tract and causing significant
economic losses worldwide. Immunodominant proteins of the variable lipoprotein and
hemagglutinin (vlhA) gene family are thought to be important for mechanisms of M.
gallisepticum-host interaction, pathogenesis, and immune evasion, but their exact role and
the overall nature of their phase variation are unknown. To better understand these
mechanisms, we assessed global transcriptomic vlhA gene expression directly from M.
gallisepticum populations present on tracheal mucosae during a seven day experimental
infection in the natural chicken host. Here we report differences in both dominant and minor
vlhA gene expression throughout the first week of infection and starting as early as day one
post infection, consistent with a functional role not dependent on adaptive immunity for
driving phase variation. Notably, data indicated that, at given timepoints, specific vlhA genes
were similarly dominant in multiple independent hosts, suggesting a non-stochastic temporal
progression of dominant vlhA gene expression in the colonizing bacterial population. The
dominant expression of a given vlhA gene was not dependent on presence of 12-copy GAA
trinucleotide repeats in the promoter region and did not revert back to the predominant vlhA
when no longer faced with host pressures. Overall, these data indicate that vlhA phase
variation is dynamic throughout the earliest stages of infection and that the pattern of
dominant vlhA expression may be nonrandom and regulated by previously unrecognized
mechanisms.
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Introduction
Mycoplasma gallisepticum, the primary etiologic agent of Chronic Respiratory Disease
(CRD) in poultry, is highly transmissible and causes severe inflammation of trachea, lungs,
and air sacs, ultimately resulting in an overall reduction in weight gain and egg production in
infected chickens. M. gallisepticum is pathogenic in other species, causing infectious sinusitis
in turkeys and conjunctivitis in house finches (2, 146). Aside from primary attachment
proteins GapA and CrmA, fibronectin binding proteins PlpA and Hlp3, sugar transport
permease MalF, and dihydrolipoamide dehydrogenase Lpd, little is understood about specific
bacterial factors affecting survival and persistence of this important avian pathogen in its
natural host (34, 194, 199, 200).
The lack of obvious homologs of traditional bacterial transcriptional regulators and
signaling factors had previously led to the thought that mycoplasmas were unable to regulate
transcription by conventional mechanisms. However, M. gallisepticum exhibits differential
gene expression in response to co-incubation with MRC-5 human lung fibroblasts(237) and
in response to various stress conditions (239, 243). These data suggest that changes in
transcription are indeed occurring as mycoplasmas respond to external stimuli and that the
regulation is, in fact, more dynamic then originally hypothesized, with genes potentially
affected by multiple regulators (238).
Potentially important for M. gallisepticum pathogenesis is the variable lipoprotein and
hemagglutinin (vlhA) family, consisting of 43 genes distributed across 5 loci and totaling
just over 10% of the entire genome in strain Rlow (195). Previous studies have indicated that
M. gallisepticum vlhA expression is dependent on the presence of exactly 12 GAA
trinucleotide repeats upstream of the gene (213–216). It has also been hypothesized that M.
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gallisepticum vlhA phase variation is stochastic, driven by anti-VlhA antibody-mediated
negative selection of the initial population and resulting in random outgrowth of bacterial
subpopulations expressing alternate vlhA(117). If that were correct, we would expect to see
varying patterns of vlhA expression from the individual chickens at each time point.
The function of VlhA proteins is still unknown, but it has been speculated to involve
immune evasion during infection (116), and variation in vlhA gene content has been loosely
associated with virulence (153).While there have been efforts to understand the antigens
expressed by M. gallisepticum in-vivo (242), there has not yet been a comprehensive global
scale, in-vivo transcriptome study of M. gallisepticum in response to the natural host over the
course of early infection. Previous studies have assessed selected in-vivo vlhA gene
expression changes using monoclonal antibodies, however methods for comprehensive vlhA
analysis were not yet available (213, 214). Now using next-generation sequencing, which
enables comprehensive gene expression assessment at the nucleotide level, we present results
indicating changes in vlhA expression of M. gallisepticum sampled directly from the tracheas
of the experimentally infected chickens over the course of a seven-day infection.

Materials and Methods

Animals
Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS,
North Franklin, CT, USA) were received and divided randomly into groups, placed in
HEPA-filtered isolators, and allowed to acclimate for one week. Non-medicated feed and
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water were provided ad libitum throughout the experiment. All animal studies were
performed in accordance with approved UConn IACUC protocol number A13-001.

Chicken infection
Stocks of M. gallisepticum strain Rlow (passage 17) were grown overnight at 37°C in
complete Hayflick’s medium until mid-log phase was reached as indicated by a color shift
from red to orange. Bacterial concentrations were determined by the OD620 and 10-fold serial
dilutions were conducted to confirm viable color changing unit titers. Bacteria were pelleted
by centrifugation at 10,000 x g for 10 min and resuspended in Hayflick’s complete medium.
Chickens were challenged intratracheally as previously described (194) with 1 x 108
CFU/200 µl.

RNA extraction
Five infected chickens were humanely sacrificed daily for a total of seven days. After
sacrifice, tracheas were excised and total RNA was extracted from each individual trachea by
washing the lumen with 1 mL TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA
was then purified using the Zymo Direct-zol RNA Miniprep Kit (Zymo Research
Corperation, Irvine, CA, USA) and standard PCR was conducted to ensure the RNA preps
were free of any DNA. RNA was quality-checked using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) and high quality samples with RNA integrity
numbers (RIN) >8 were utilized to construct cDNA libraries.
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To enrich for bacterial RNA, total RNAs were subjected to a polyA depletion step to
remove the eukaryotic mRNA using the NEBNext Poly(A) mRNA Magnetic Isolation
Module (New England Biolabs, Ispwich, MA, USA). Briefly, 5 μg of total RNA combined
with an equal volume of bead binding buffer was bound to the poly-T oligo-attached
magnetic beads at 65°C for five minutes. The remaining supernatant was collected, cleaned
and concentrated using the Zymo clean and concentrator -25 kit (Zymo Research
Corperation) and eluted in 25μl RNase-free water.
Both prokaryotic and eukaryotic ribosomal RNA were removed from 2.5 μg of polyA depleted RNA using the RiboZero Magnetic Gold kit (Epidemiology) (Illumina Inc., San
Diego, CA, USA) following the manufacturer’s instructions. Each rRNA depleted RNA
sample obtained after cleaning and concentrating with the Zymo clean and concentrator -25
kit (Zymo Research Corporation) was eluted in 25 μl of RNase free water and used to create
a cDNA library.

Illumina Sequencing
The cDNA libraries were created using the Illumina TruSeq Stranded mRNA Library
Preparation Kit (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s
instructions starting at “Make RFP” (step 14, p.56) of the Illumina TruSeq RNA Sample
Preparation v2 (HT) protocol. Briefly, 10-400 ng of purified mRNA was fragmented and
used to synthesize first-strand cDNA using reverse transcriptase and random hexamer
primers. Second-strand cDNA synthesis was performed using dUTP, DNA polymerase, and
RNase. The products were amplified by PCR and purified after end repair and adaptor
ligations.
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The cDNA libraries were assessed for quantity using the Qubit 2.0 fluorometer
(Invitrogen) and correct fragment size (~260 bp) using the Agilent TapeStation 2200 (Agilent
Technologies). Libraries were then normalized to two nM, pooled, denatured, and sequenced
on a NextSeq500 Sequencing platform (Illumina Inc.) using a 75 bp paired-end approach.

RNA-seq Analysis
Fastq data were assembled and mapped, and differential gene expression assessed,
using Rockhopper, an RNAseq analysis program with algorithms specifically designed for
the

bacterial

gene

structures

(http://cs.wellesley.edu/~btjaden/Rockhopper/) (244, 245).

and

transcriptomes

Bowtie2 parameters allowing 0

mismatches were used to map sequence reads to the Rlow genomic template (195). The data
were normalized by the standard method of determining the ratio of reads per kilobase of
transcript per million reads mapped (RPKM), allowing for comparisons both within and
between samples. The fold change was determined from the log2 transformation of the
RPKM between two samples. The differential gene expression was determined by pair-wise
comparisons between the normalized expression values of a given vlhA gene between two
different days. The program-generated p-value was used to determine the significance of the
differential gene expression by calculating q-values based on the Benjamini–Hochberg
correction with a false discovery rate <1%. Differences in expression values were considered
significant when q < 0.02 (245).

Sequencing of culture-passed bacteria
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Mycoplasma cultures recovered from tracheas of the experimentally infected birds at
day seven postinfection were passed five or ten times in Hayflick’s complete medium.
Cultures were then grown to mid-log phase for DNA extraction using Chelex reagent
(BioRad, Hercules, CA, USA) or RNA extraction, enrichment, and sequencing as was
described with the trachea samples above.
Targeted sequencing of vlhA 2.02 gene promoter sequences to query GAA repeat
copy number was performed directly on specific PCR amplicons. PCR primers targeting the
vlhA 2.02 promoter region designed using the M. gallisepticum R(low) genomic sequence
(GenBank

accession

no.

AE015450)

(195)

were

as

follows:

forward

5’-

GATGAGATTATCAAGCTTTTAGATG-3’ and reverse
5’-CTGAACGAATCAAAGAGTTACAGC-3’. PCR was performed using Amplitaq
(Invitrogen), 20 pmol of each primer and 200-300 ng DNA with the following cycling
conditions: 94°C for 5 min, followed by 40 cycles at 94°C for 15 sec, 54°C for 30 sec, and
72°C for 1 min with a final extension of 72°C for 10 min. Amplicons were purified using the
MinElute Reaction Cleanup Kit (Qiagen, Valencia, CA, USA) to remove excess primers.
Sequencing was performed using 2 μl BigDye Terminator Mix (Invitrogen), 10 pmol
of primer, and 300 ng of DNA (246). Excess dye terminators were removed with AutoSeq
G-50 spin columns (Amersham Biosciences, Piscataway, NJ, USA), and the sequencing was
performed by the University of Connecticut Biotechnology Center. Using Sequencher
software (Gene Codes, Ann Arbor, MI, USA), the sequences were compared to the Rlow
genome and the number of GAA trinucleotide repeats upstream of the gene start codon were
assessed.
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Results

M. gallisepticum input vlhA expression
In broth grown M. gallisepticum strain Rlow input cultures, data here indicated that 31
vlhAs were expressed with an average normalized expression value of 719. vlhA 3.03 was the
predominant vlhA expressed in this culture, with an RPKM value >12,000 (Fig.1). This vlhA
is preceded by exactly 12 GAA repeats (11), a characteristic previously thought to be
necessary for expression (12-15). vlhA 3.03 was not the only vlhA expressed, however, as
several other vlhAs, including 2.02, 5.06, and 4.07, were expressed at levels (RPKM of 1500
– 2300) above the average RPKM (1455) of all genes in the genome that were expressed.
This indicated that, while vlhA 3.03 expression predominated, additional vlhAs that were not
preceded by 12 GAA repeats were expressed at minor levels in the cultured experimental
input population.

M. gallisepticum vlhA expression over the course of infection
Over the course of the seven-day infection, the vlhA expression profile changed
dramatically. The expression of vlhA 3.03 showed an initial increase at day one postinfection
and then decreased daily throughout the experiment (Fig 2). Over the course of infection,
there was a 34-fold total decrease in vlhA 3.03 expression (q<0.0001), with the largest
change being a 4.5-fold decrease between days 5 and 6 postinfection (q< 0.0001).
While expression of vlhA 3.03 decreased early in infection, expression of vlhA 4.07
and its tandem repeat, vlhA 4.07.6 began to increase as early as one day postinfection. These
expression levels peaked at two days postinfection (3.7-fold higher than input culture) before
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decreasing over the remainder of the seven-day infection (Fig 2). Similarly, as vlhA 4.07 and
4.07.6 decrease in expression, vlhA 4.08 and its tandem repeat, vlhA 4.07.1 showed increased
expression until peaking at seven days postinfection with 31-fold higher (q<0.0001)
expression than levels of input cultures (Fig. 2). Finally, there was an initial increase in vlhA
5.05 expression at one day postinfection, followed by decreasing expression through the time
course. The vlhA expression profile observed here at day seven postinfection was consistent
with that of a previous pilot experiment (data not shown). Taken together, these changes in
vlhAs expression were not completely random, and appeared to be relatively coordinated as
similar vlhA profiles were seen in five independently infected birds at each time point
postinfection.

M. gallisepticum vlhA expression in recovery cultures
From infected birds sacrificed seven days postinfection, M. gallisepticum was
recovered directly from tracheas into Hayflick’s complete medium and serially passed invitro. After either five or 10 passages, M. gallisepticum populations were predominantly
expressing vlhA 2.02 with an average RPKM value of 8463, a 4.4-fold increase relative to
vlhA 2.02 expression observed directly on tracheal mucosae at seven days postinfection (q<
0.0001) (Fig 3A). The M. gallisepticum recovered after one passage in-vitro displayed a
transitional vlhA profile with vlhA 3.03 and 2.02 increasing in expression and vlhA 4.07.1 and
4.08 decreasing in expression (Data not shown). These data suggest the expression of vlhA
2.02 is favorable for the pathogen after recovery from the host trachea and passage in a
nutritive medium. Several other vlhAs, including vlhA 3.03, were also expressed in the
recovery cultures, but at levels much lower than vlhA 2.02. Interestingly, vlhA 3.03 was
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expressed at a much lower, non-dominant level (4.5-fold) than in the initial input culture (Fig
3A).
When the promoter region upstream of the highly expressed vlhA 2.02 gene from the
recovery cultures was PCR amplified and sequenced, data revealed only a single GAA
trinucleotide upstream of the start codon, suggesting that 12 GAA repeat copies might not be
essential for the expression of a given vlhA, at least in the in-vitro culture following direct
recovery from the trachea (Fig 3B). Furthermore, we observed no changes in the genomic
nucleotide sequence upstream of vlhA 2.02 in the cultures recovered from the infected
animals and passed in-vitro compared to the broth grown input culture.

Discussion
This study has demonstrated the global population changes in M. gallisepticum vlhA
gene expression assessed directly from tracheas of experimentally infected chickens over the
course of a seven day infection. It was important to recover the M. gallisepticum RNA
directly from the trachea into the TRIzol reagent to minimize the time between collection and
extraction, as we observed significant changes in the gene expression profile of M.
gallisepticum after just one single passage in culture medium (data not shown). This study
design allowed for the capture of the most accurate representation of the vlhA profile in-vivo
at each time point during the infection process.
These observed changes in expression are likely not antibody mediated, as the decrease
in expression of vlhA 3.03 is seen as early as two days postinfection, well before the
formation of specific antibodies(193). This finding is in agreement with a previous study that
demonstrated that vlhA expression in infected chickens switches prior to the host mounting
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an antibody response (214). However, this study greatly expands on those initial observations
to include the expression status of all of the vlhAs over the early course of infection.
These findings are significant as they imply that the driving force behind the shift in
vlhA expression is not controlled entirely by the adaptive immune system. These data suggest
that another mechanism is, at least in part, controlling changes in expression of the vlhA
genes in-vivo.
It is possible that early phase variation could be driven, in part, by the alterations in the
cellular architecture of the tracheas during infection. As the infection progresses, the host
cells experience denuding of cilia, squamous cell metaplasia, and eventual destruction of the
host cell membranes. It is possible that the M. gallisepticum vlhA expression is changing in
response to these alterations and the pathogen is expressing a specific set of vlhAs to best
persist in the current environment. Consistent with the hypothesis that M. gallisepticum vlhA
expression is nonrandom and follows progression of pathogenesis in the host, vlhA 1.07 and
4.01 reported by Ron et al. (242) to express significant antigens at two to five weeks
postinfection were not predominantly expressed within one week postinfection as reported
here.
Data here indicate that despite expressing different vlhAs in the host at day seven
postinfection, vlhA 2.02 is the predominant vlhA expressed in the M. gallisepticum
population following recovery and passage in Hayflick’s complete medium. Unanticipated
was the dominance of vlhA 2.02 and the lack of reversion to predominant vlhA 3.03
expression observed in the broth grown input culture. However, in these recovery cultures,
vlhA 2.02 was also accompanied by the expression (albeit at lower levels) of several other
vlhAs in the population, including vlhA 3.03 and 5.13, suggesting that more than one vlhA is
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expressed at a given time point in the population. These data also indicate that M.
gallispticum may favor the expression of several vlhAs (vlhA 3.03, 2.02, and 5.13) when no
longer faced with the pressures of surviving in the airway of the host
Data here also demonstrated that 12 GAA trinucleotide repeats are not essential for the
expression of a given vlhA, since the vlhA 2.02 highly expressed in the recovery samples
does not contain 12 GAA repeats in upstream sequences. It had previously been hypothesized
that 12 GAA repeats were necessary for expression of a given vlhA because it allowed for the
correct spacing between flanking sequences for necessary accessory factors to bind, as M.
gallisepticum does not possess a robust consensus sequence at -10 and -35 (216). The
observed expression of vlhA genes without the 12 GAA repeats upstream suggest that there
may be another mechanism at play that is responsible, at least in part, for the regulation of
the vlhA expression in M. gallisepticum.
These results, revealing global vlhA expression changes over the course of early
infection, are important in elucidating mechanisms of persistence, colonization, and overall
pathogenesis of M. gallisepticum in the natural host. Full and complete understanding of
these mechanisms will provide information likely to be critical for development of rationally
designed M. gallisepticum therapeutics and vaccines.
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Figure 1. The vlhA expression profile of the broth grown M. gallisepticum input cultures as
determined from RNA sequencing.
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Figure 2. The vlhA expression profile of M. gallisepticum extracted directly from tracheas of
experimentally infected birds over the course of the seven day infection as determined
though RNA sequencing. Each data point is an average RPKM value from five animals (with
the exception of the broth sample). Error bars show SEM. Key statistically significant
changes between two time points are indicated by paired upper and lower case letters for the
following genes: vlhA 3.03 (A/a and A’/a’), and vlhA 4.07.1/4.08 (B/b).
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Figure 3. The vlhA expression of the M. gallisepticum recovered and cultured at five (5’) or
ten (10’) passes from the tracheas of the two different infected birds at seven days
postinfection (A). Only vlhAs with an average RPKM >100 are displayed. The sequence of
the region upstream of the highly expressed vlhA 2.02 in the cultures recovered from the
infected birds (B).
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CHAPTER 3:

The vlhA profile of Mycoplasma gallisepticum predominantly expressing an alternate
vlhA over a two day in-vivo infection
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Abstract
Mycoplasma gallisepticum is the primary etiologic agent of Chronic Respiratory
Disease in poultry, a disease largely affecting the respiratory tract and causing significant
economic losses worldwide. Proteins of the variable lipoprotein and hemagglutinin (vlhA)
gene family are thought to be important for mechanisms of M. gallisepticum-host interaction,
pathogenesis, and immune evasion, but their exact role and the overall nature of their phase
variation are unknown. To better understand these mechanisms, we assessed global
transcriptomic vlhA gene expression directly from M. gallisepticum populations present on
tracheal mucosae during an experimental infection in the natural chicken host with a strain
expressing an alternate dominant vlhA. Here we report that the in vivo vlhA expression
profile of M. gallisepticum when chickens are infected with a culture predominantly
expressing vlhA 2.02 is similar to that seen when the M. gallisepticum predominantly
expressing vlhA 3.03 is used for infection during early stages of infection. This indicates that
the progression of vlhA expression, especially the initial predominantly expression of vlhA is
likely important during the earliest stages of the infection process.
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Introduction

Mycoplasma gallisepticum, a highly transmissible avian pathogen, contributes to
chronic respiratory disease (CDR), a pathological syndrome largely affecting the respiratory
tracts of poultry causing inflammation of the air sacs, lungs, and trachea causing significant
monetary losses world-wide (2). M. gallisepticum has also been linked to infectious sinusitis
in turkeys and severe conjunctivitis in house finch(2, 247).
Despite much effort, little is completely understood about the mechanisms of survival
and persistence or pathogenic mechanisms employed by this organism (34, 194, 237, 199,
200, 242). Potentially important in the virulence of the organism is the phase-variable
lipoprotein hemagglutinin gene family (vlhA)(195) as they have been shown to differ in both
size and genomic location in strains varying in levels of virulence (153). Initial studies have
reported that vlhA expression is stochastic, and due to radom outgrowth after anti-VlhA
antibody mediated negative selection (117). It has also been reported that the expression of a
single vlhA gene occurs only when that gene is preceded by exactly 12 GAA triucleotide
repeats in the promoter region (213, 215, 216, 224). However, despite this report, a recent
study has shown that at given timepoints, specific vlhA genes were similarly dominant in
multiple independent hosts, suggesting a non-stochastic temporal progression of dominant
vlhA gene expression and that the expression was not completely dependent on the presence
of 12 GAA trinuclotide repeats (248).
Here, using next-generation sequencing, we extend the understanding of vlhA gene
expression, specially the importance of the vlhA 3.03, the initial immuno-dominat vlhA at one

55

day post-infection. We report the results of the global vlhA gene expression profile when the
input population is expressing an alternate dominant vlhA, vlhA 2.02.

Materials and Methods

Animals
Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS,
North Franklin, CT, USA) were received and divided randomly into groups, placed in
HEPA-filtered isolators, and allowed to acclimate for one week. Non-medicated feed and
water were provided ad libitum throughout the experiment. All animal studies were
performed in accordance with approved UConn IACUC protocol number A13-001.

Chicken infection
M. gallisepticum R strain cultures stabilized to express an alternate vlhA (vlhA 2.02)
have been identified (248) were used as the input cultures in. As a positive control, M.
gallisepticum strain Rlow (passage 17) were also used for inoculation.10-fold serial dilutions
were conducted to confirm viable color changing unit titers. Bacteria were pelleted by
centrifugation at 10,000 x g for 10 min and re-suspended in Hayflick’s complete medium.
Chickens were challenged intratracheally as previously described (248).

RNA extraction
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Four infected chickens from each group were humanely sacrificed at day 1 and day 2
post infection. After sacrifice, tracheas were excised and total RNA was extracted from each
individual trachea by washing the lumen with 1 mL TRIzol reagent (Invitrogen, Carlsbad,
CA, USA). Total RNA was then purified using the Zymo Direct-zol RNA Miniprep Kit
(Zymo Research Corperation, Irvine, CA, USA) and standard PCR was conducted to ensure
the RNA preps were free of any DNA. RNA was quality-checked using an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and high quality samples with
RNA integrity numbers (RIN) >8 were utilized to construct cDNA libraries.
M. gallisepticum RNA was enriched as previously described (248). Briefly, total
RNAs were subjected to a polyA depletion step to remove the eukaryotic mRNA using the
NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ispwich, MA,
USA). Briefly, 5 μg of total RNA combined with an equal volume of bead binding buffer
was bound to the poly-T oligo-attached magnetic beads at 65°C for five minutes. The
remaining supernatant was collected, cleaned and concentrated using the Zymo clean and
concentrator -25 kit (Zymo Research Corperation) and eluted in 25μl RNase-free water.
Both prokaryotic and eukaryotic ribosomal RNA were removed from 2.5 μg of polyA depleted RNA using the RiboZero Magnetic Gold kit (Epidemiology) (Illumina Inc., San
Diego, CA, USA) following the manufacturer’s instructions. Each rRNA depleted RNA
sample obtained after cleaning and concentrating with the Zymo clean and concentrator -25
kit (Zymo Research Corporation) was eluted in 25 μl of RNase free water and used to create
a cDNA library.

Illumina Sequencing
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The cDNA libraries were created using the Illumina TruSeq Stranded mRNA Library
Preparation Kit (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s
instructions starting at “Make RFP” (step 14, p.56) of the Illumina TruSeq RNA Sample
Preparation v2 (HT) protocol. Briefly, 10-400 ng of purified mRNA was fragmented and
used to synthesize first-strand cDNA using reverse transcriptase and random hexamer
primers. Second-strand cDNA synthesis was performed using dUTP, DNA polymerase, and
RNase. The products were amplified by PCR and purified after end repair and adaptor
ligations.
The cDNA libraries were assessed for quantity using the Qubit 2.0 fluorometer
(Invitrogen) and correct fragment size (~260 bp) using the Agilent TapeStation 2200 (Agilent
Technologies). Libraries were then normalized to two nM, pooled, denatured, and sequenced
on a NextSeq500 Sequencing platform (Illumina Inc.) using a 75 bp paired-end approach.

RNA-seq Analysis
Fastq data were assembled and mapped, and differential gene expression assessed,
using Rockhopper, an RNAseq analysis program with algorithms specifically designed for
the

bacterial

gene

structures

(http://cs.wellesley.edu/~btjaden/Rockhopper/) (244, 245).

and

transcriptomes

Bowtie2 parameters allowing 0

mismatches were used to map sequence reads to the Rlow genomic template (195). The data
were normalized by the standard method of determining the ratio of reads per kilobase of
transcript per million reads mapped (RPKM), allowing for comparisons both within and
between samples. The fold change was determined from the log2 transformation of the
RPKM between two samples. The differential gene expression was determined by pair-wise
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comparisons between the normalized expression values of a given vlhA gene between two
different days. The program-generated p-value was used to determine the significance of the
differential gene expression by calculating q-values based on the Benjamini–Hochberg
correction with a false discovery rate <1%. Differences in expression values were considered
significant when q < 0.02 (245).

Results
When chickens are experimentally challenged with an M. gallisepticum strain
predominantly expressing an alternate vlhA, the vlhA expression profile of the bacteria
recovered from the tracheal mucosa is very similar to that of a wild type strain expressing
vlhA 3.03 predominantly (Fig 1).
In the M. gallisepticum recovered from experimentally infected chickens, we
observed a sharp increase in the expression of the vlhA 3.03 at one day post infection with a
14.8-fold increase in expression compared to the vlhA 3.03 gene expression in the input
population. Followed by this sharp increase, was a 6.1-fold decrease in expression of vlhA
3.03 by two days post infection Fig 1 and Table 1). This pattern was very similar to that of
the initial wild-type input culture in which that population was predominantly expressing
vlhA 3.03 (see chapter 2).
Additionally, we observed a similar pattern of expression with vlhA 4.07 and its
tandem repeat vlhA 4.07.6, where there was a 80.1-fold and 78.7-fold increase compared to
the input population, respectively, in the expression at day one post infection. This was then
followed by a 5.8- and 5.4-fold decrease in expression by day two post infection (Fig1 and
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Table 1). This pattern is also observed when the wild type input cultures are predominantly
expressing vlhA 3.03 (see chapter 2).
Surprisingly, vlhA 2.02, the predominant vlhA expressed in the challenge culture,
stayed relatively stable through one day post infection displaying only a slight 1.1-fold
increase in expression. However, the expression level of vlhA 2.02 showed a 9.7-fold
reduction in expression level by two days post infection (Fig 1 and Table 1). This differs
from the vlhA expression profile of wild type M .gallisepticum initially expressing vlhA 3.03
predominantly. When vlhA 3.03 was predominantly expressed in the input population, vlhA
2.02 did not show an expression level above background at any point during the seven day
infection study (see chapter 2).

Discussion
Here we report the initial vlhA expression profile of M. gallisepticum predominantly
expressing vlhA 2.02 recovered from the chicken tracheas during the early course of
experimental infection. The vlhA expression profile was very similar to that of the wild type
M. gallisepticum strains with a sharp increase in the expression of vlhA 3.03 at one day post
infection and a decrease in expression by two days post infection.
These data suggest that vlhA 3.03 is likely very important in the early infection
process of M. gallisepticum as it is highly expressed at one day post infection regardless if it
was predominant in the initial culture used for challenge or not.
Additionally, we observed an increase in the expression of vlhA 4.07 and 4.07.6 at
one day post infection, a pattern also observed when the initial input culture was
predominantly expressing vlhA 3.03. This suggests that, while not the predominant vlhA
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genes expressed, they still may play a vital role for M. gallisepticum in the earliest stages of
infection.
It is important to note that, while the input population used in this second study was
predominantly expressing vlhA 2.02, vlhA 3.03 was still expressed, albeit at a much lower
level, in this population. It is possible that the perceived increase in the expression of vlhA
3.03 at day one post infection is due to the fact that only those M. gallisepticum expressing
vlhA 3.03 were able to colonize the trachea at that time. Either way, these data emphasize the
importance of the predominant expression of vlhA 3.03 in the earliest stages of infection.
In totality these data demonstrate that even when the predominant vlhA expression is
altered, M. gallisepticum still undergoes the same non-stochastic temporal progression of
expression over the earliest stages of infection. This suggests that progression of vlhA
expression is likely important in the initial stages of the infection process in the chicken
trachea.
Further insight into these patterns of expression may lead to a more complete
understanding of the pathogenic mechanisms employed by M. gallisepticum during early
stages of the infection process.
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Figure 1. The vlhA gene expression profile of the M. gallisepticum strain predominantly
expressing vlhA 2.02 from the tracheal mucosa of experimentally infected birds over a twoday infection.
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Table 1. The fold change of select vlhA genes over from the M. gallisepticum strain
predominantly expressing vlhA 2.02 from the tracheal mucosa of experimentally infected
birds over a two-day infection.
vlhA gene

Fold Change
Broth vs Day 1

Day 1 vs Day 2

vlhA 3.03

+14.8

-6.1

vlhA 4.07

+80.1

-5.8

vlhA 4.07.6

+78.7

-5.4

vlhA 2.02

+1.1

-9.7
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CHAPTER 4

CONCLUSIONS AND DISCUSSION
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Collectively, these data significantly further our understanding of the M.
gallisepticum phase-variable vlhA gene expression, showing that the vlhA genes exhibit a
non-stochastic temporal progression of expression and altering the starting vlhA does not
alter the predominant expression of vlhA 3.03 at one day post infection.
We observed changes in vlhA gene expression as early as 1-2 days post infection,
well before the formation of specific antibodies (193), suggesting that the changes observed
at these earliest stages of infection are not influenced by the adaptive immune system of the
host,. However, it is very likely that as the disease progresses, the host adaptive immune
response will play a role in the vlhA genes expression patterns as it has been demonstrated
that a change in vlhA expression can be forced in-vitro by the addition of specific antibodies
(249). These data suggest that another mechanism is, at least in part, responsible for the
changes in expression of the vlhA genes in-vivo during the earliest stages of the infection
process.
It is possible that these changes in vlhA expression could be in response to the
alterations in the cellular architecture of the tracheas during infection. As the infection
progresses, the host cells experience denuding of cilia, squamous cell metaplasia, and
eventual destruction of the host cell membranes. It is possible that the M. gallisepticum vlhA
expression is changing in response to these alterations and the pathogen is expressing
successive specific sets of vlhAs to best persist in the current environment.
This is similar to what has been reported in Wolbachia species, a rickettsial bacterium
which infects invertebrate organisms lacking adaptive immune systems. Wolbachia variable
surface proteins are involved in host cell attachment and vary their expression in response to
non-immune environmental pressures (250).
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As the function of VlhAs is still unknown at this time, it is also possible that these
gene products could be functioning in sensing the current environment and relaying messages
into the cell. It is also possible that these gene products could be involved in the transport of
essential nutrients and molecules, as these VlhAs are surface exposed. M. gallisepticum
could be altering expression of vlhAs in response to a change in nutrient availability in the
current environment.
Data here also indicated that the vlhAs exhibit a non-stochastic, temporal progression
of expression, as vlhAs were similarly dominant in multiple independent hosts in repeated
studies. This is particularly interesting as previous studies have hypothesized that that vlhA
expression was stochastic, and due to radom outgrowth after anti-VlhA antibody mediated
negative selection (214).
Unanticipated was the dominance of vlhA 2.02 and the lack of reversion to
predominant vlhA 3.03 expression observed in the broth grown input culture. However, in
these recovery cultures, vlhA 2.02 was also accompanied by the expression (albeit at lower
levels) of several other vlhAs in the population, including vlhA 3.03 and 5.13, suggesting that
more than one vlhA is expressed at a given time point in the population. These data also
indicate that M. gallispticum may favor the expression of several vlhAs (vlhA 3.03, 2.02, and
5.13) when no longer faced with the pressures of surviving in the airway of the host.
Data here also demonstrated that 12 GAA trinucleotide repeats are not essential for
the expression of a given vlhA, since the vlhA 2.02 highly expressed in the recovery samples
does not contain 12 GAA repeats in upstream sequences. It had previously been hypothesized
that 12 GAA repeats were necessary for expression of a given vlhA because it allowed for the
correct spacing between flanking sequences for necessary accessory factors to bind, as M.
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gallisepticum does not possess a robust consensus sequence at -10 and -35 (216). The
observed expression of vlhA genes without the 12 GAA repeats upstream suggests that there
may be another mechanism at play that is responsible, at least in part, for the regulation of
the vlhA expression in M. gallisepticum.
Additionally, we found that M. gallisepticum strains expressing an alternate dominant
vlhA still display a very similar expression pattern over the earliest stages of the infection,
showing a sharp increasing the expression of vlhA 3.03 at one day post infection, followed a
decrease by two days post infection. Additionally the initial increase in the expression of
vlhA 4.07 and its tandem repeat, 4.07.6 was observed, followed by the decline in expression
by two days post infection. These data suggest that vlhA 3.03 may play a critical role in the
infection process of M. gallisepticum in the trachea of the chicken host as it is consistently
highly and predominantly expressed at day one post infection regardless of the predominant
vlhA expressed in the input culture. Additionally, vlhAs 4.07 and 4.07.6 are likely important
during the earliest stages of the infection process as their increased expression is repeatedly
observed at day one post infection, regardless of the predominantly expressed vlhA in the
challenge culture.
Taken together these data demonstrate that even when the predominant vlhA
expression is altered, M. gallisepticum still undergoes the same non-stochastic temporal
progression of expression over the earliest stages of infection. This suggests that progression
of vlhA expression is likely important in the initial stages of the infection process in the
chicken trachea.
Specific vlhA gene products are likely to have specific functions; however, the exact
roles are unknown at this time. These gene products could be involved in attachment to host
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cells to prevent clearance, sensing of the surrounding environment, or transport of nutrients
into the cell. Regardless of the function of these products, M. gallisepticum expresses these
genes in a coordinated, non-random manner over the course of early infection in the chicken
trachea. This non-stochastic vlhA expression pattern is still displayed in-vivo even when the
initial challenge culture expression pattern is altered.
The data suggest that these gene products are important in early infection in the
natural host and each VlhA (or specific set of VlhAs) may have a unique function. M.
gallisepticum is likely expressing a specific subset of vlhA genes in order to best persist in the
current environment. If there were no change in the environment M. gallisepticum is
persisting in, it appears there is little to no change in the predominant vlhA expressed. For
example when M. gallisepticum is passed numerous times in-vitro, the predominant vlhA
gene expression remains stable. However, when it is exposed to the cells of the chicken
trachea, the vlhA profile begins to change immediately, as early as day one post infection,
suggesting that M gallisepticum is responding to the change in environment and likely
expressing a subset of vlhAs to best persist in that environment.
Furthermore, once M. gallisepticum is recovered from the trachea of experimentally
infected chickens and passed in-vitro, the vlhA expression profile changes again, suggesting,
yet again, that M. gallisepticum is expressing a very specific subset of vlhA genes to best
survive in the current environment.
Overall, these data indicate that vlhA phase variation is dynamic throughout the
earliest stages of infection and that the patterns of dominant vlhA gene expression are
nonrandom and regulated by a currently unknown mechanism(s). These data also stress the
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importance of the expression of vlhA 3.03 during the initial stages of infection, furthering our
understanding of phase variation in M. gallisepticum.
These results, revealing global vlhA expression changes over the course of early
infection, are important in elucidating mechanisms of persistence, colonization, and overall
pathogenesis of M. gallisepticum in the natural host. We can now begin to further understand
vlhA gene expression and phase variation in M. gallisepticum. Full and complete
understanding of these patterns of expression will help to provide insight that may be critical
for the development of rationally designed therapeutics and vaccines.

Future Directions
Although beyond the scope of this project, it will be beneficial to determine if there is
tissue specificity for different vlhA genes. For example, it is possible that different vlhA genes
are dominantly expressed when exposed to varying cell types in tissues of the host, allowing
for optimal survival in the different tissues. Additionally, as infection with M. gallisepticum
progresses in the respiratory tract, the architecture of the trachea changes as well as the cell
type predominating as metaplasia occurs. The M. gallisepticum could be altering the
predominant vlhA expressed as a response to the changing cell type in the chicken trachea at
a given time point and expressing the best vlhA to persist in that current environment.
Examining the global vlhA profile in various host tissues including, air sacs, lungs, and
oviducts and understanding the driving force behind the changes in vlhA gene expression in
the trachea would provide valuable information into the specificity of the vlhA expression
profile.
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Given that vlhA 3.03 appears to be important in the initial stages of the infection
process, as it is the predominant vlhA at day one post infection, regardless of what the
starting predominant vlhA is in the input culture, it will beneficial to assess the virulence of
mutants lacking vlhA 3.03 in the natural host. Screening our transposon mutant library, a
vlhA 3.03 mutant could be identified and used to experimentally challenge chickens and
assess the virulence of the mutant and to determine the plasticity of the vlhA profile. These
data would indicate the necessity (or lack thereof) of the expression of vlhA 3.03 to attach,
colonize, and causes pathology in the respiratory organs of chickens.
In conjunction with this study, the lab is also sequencing the host RNA obtained from
the same samples used in this study over the course of early infection. This will allow a
glimpse into the interplay between the pathogen and its natural host over the initial stages of
the infection process, furthering our understanding of the pathogenesis of M. gallisepticum
and how the host responds to that challenge. Assessing these data concurrently could provide
insight into the host factors that could be playing a role in the non-stochastic temporal
progression of vlhA expression.
Additionally, examining the vlhA profile of live attenuated vaccine strains will
enhance our understanding of the progression and importance of vlhA gene expression. These
strains do not cause the same level of pathology in the trachea as wild-type Rlow strains, and
therefore, may display a different vlhA profile over the initial stages of infection. Preliminary
data suggest that the in vivo vlhA expression profile of the live attenuated vaccine strains
Mg7 and GT5 is different than that of wild-type Rlow, with the expression of vlhA 3.03
continually increasing over the first two days of infection. This could be due to the fact that
the vaccine strains do not cause significant damage to the tracheal mucosa as severe as Rlow,
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therefore the environment is not changing significantly, and the M. gallisepticum is not
stimulated to change predominant expression from vlhA 3.03.
Understanding these changes in vlhA expression and the effects those genes have on
the virulence and persistence of the pathogen will be important in elucidating mechanisms of
colonization, persistence, and overall pathogenesis of M. gallisepticum in the natural host
and will provide information likely to be critical for development of rationally designed M.
gallisepticum therapeutics and vaccines.
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